Thinking of joining a study?

Register your interest

Become a volunteer?

Clinical trials for Cancer in United States

7241 results

Sort By:

Lay Coach-Led Early Palliative Care for Underserved Advanced Cancer Caregivers: The Project ENABLE Cornerstone RCT

Study ID: NCT04318886
Start Date: 2020-01-07
End Date: 2027-06-30
Study Type

Interventional

Study Phase

Phase3

No. of Participants

412

Intervention / Treatment

ENABLE Cornerstone

Sponsor

University of Alabama at Birmingham

Source: clinicaltrials.gov

Share:
Add to list

Conventional or Hypofractionated Radiation Therapy in Treating Patients With Prostate Cancer

Study ID: NCT03987386
Start Date: 2019-05-30
End Date: 2025-11-01
Study Type

Interventional

Study Phase

Phase3

No. of Participants

186

Intervention / Treatment

Hypofractionated Radiation Therapy

Quality-of-Life Assessment

Administration questionnaire

Radiation Therapy

Sponsor

M.D. Anderson Cancer Center

Source: clinicaltrials.gov

Share:
Add to list

EXERT-BCH Exercise Regimen to Improve Muscle Mass After Treatment of Breast Cancer

Study ID: NCT06115486
Start Date: 2024-01-09
End Date: 2027-01
Study Type

Interventional

Study Phase

Not Applicable

No. of Participants

30

Intervention / Treatment

Control Arm ACSM Guidelines

Experimental Arm 6-12-25 repetitions per set

Sponsor

Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)

Source: clinicaltrials.gov

Share:
Add to list

Comparing Brief Behavioral Therapy (BBT-CI) and Healthy Eating Education Learning (HEAL) for Cancer-Related Sleep Problems While Receiving Chemotherapy

Study ID: NCT04829539
Start Date: 2021-06-24
End Date: 2027-06-30
Study Type

Interventional

Study Phase

Phase3

No. of Participants

400

Intervention / Treatment

Behavioral Intervention

Behavioral Intervention

Quality-of-Life Assessment

Administration questionnaire

Sponsor

University of Rochester NCORP Research Base

Source: clinicaltrials.gov

Share:
Add to list

A Study to Assess BMS-986458 Alone and in Combination With Anti-lymphoma Agents in Relapsed/Refractory Non-Hodgkin Lymphomas

Study ID: NCT06090539
Start Date: 2023-12-29
End Date: 2028-10-28
Study Type

Interventional

Study Phase

Phase2

No. of Participants

308

Intervention / Treatment

BMS-986458

Rituximab

Glofitamab/Obinutuzumab

Mosunetuzumab

Sponsor

Bristol-Myers Squibb

Source: clinicaltrials.gov

Share:
Add to list

Immunotherapy Platform Study in Platinum Resistant High Grade Serous Ovarian Cancer

Study ID: NCT04918186
Start Date: 2022-05-03
End Date: 2025-12-31
Study Type

Interventional

Study Phase

Phase2

No. of Participants

60

Intervention / Treatment

Durvalumab

He sold 011

He sold 021

ENB003

Tripleimab

Sponsor

Canadian Cancer Trials Group

Source: clinicaltrials.gov

Share:
Add to list

FearLess in NeuroOncology

Study ID: NCT06989086
Start Date: 2025-06-18
End Date: 2028-12-31
Study Type

Observational

Study Phase

Not Applicable

No. of Participants

112

Intervention / Treatment

Fearless in Neuro-Oncology

Sponsor

Virginia Commonwealth University

Source: clinicaltrials.gov

Share:
Add to list

HSV-tk + Valacyclovir + SBRT + Chemotherapy for Recurrent GBM

Study ID: NCT03596086
Start Date: 2017-12-11
End Date: 2025-12-30
Study Type

Interventional

Study Phase

Phase2

No. of Participants

62

Intervention / Treatment

ADV/HSV-tk (gene therapy)

Sponsor

David Baskin MD

Source: clinicaltrials.gov

Share:
Add to list

Molecular Epidemiology of Biliary Tree Cancers

Study ID: NCT05179486
Start Date: 2017-09-25
End Date: 2027-02-02
Study Type

Observational

Study Phase

Not Applicable

No. of Participants

1500

Intervention / Treatment

Biospecimen Collection

Administration questionnaire

Sponsor

M.D. Anderson Cancer Center

Source: clinicaltrials.gov

Share:
Add to list

A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Mosunetuzumab + Lenalidomide (+Len), and the Safety, Tolerability, and Pharmacokinetics of SC Versus IV Mosunetuzumab + Len in Participants With Follicular Lymphoma

Study ID: NCT04246086
Start Date: 2020-08-12
End Date: 2030-10-15
Study Type

Interventional

Study Phase

Phase2

No. of Participants

237

Intervention / Treatment

Mosunetuzumab (IV)

Tocilizumab

Lenalidomide

Mosuntuzumab (SC)

Sponsor

Hoffmann-La Roche

Source: clinicaltrials.gov

Share:
Add to list